TEMSIROLIMUS for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 213 adverse event reports in the FDA FAERS database where TEMSIROLIMUS was used for Renal cell carcinoma.
Most Reported Side Effects for TEMSIROLIMUS
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Disease progression | 158 | 9.6% | 66 | 50 |
| Death | 136 | 8.3% | 135 | 14 |
| Stomatitis | 100 | 6.1% | 17 | 51 |
| Anaemia | 89 | 5.4% | 16 | 44 |
| Neoplasm progression | 84 | 5.1% | 33 | 24 |
| Vomiting | 81 | 4.9% | 13 | 52 |
| Diarrhoea | 79 | 4.8% | 9 | 51 |
| Febrile neutropenia | 78 | 4.7% | 1 | 66 |
| Pneumonia | 76 | 4.6% | 23 | 52 |
| Off label use | 75 | 4.6% | 15 | 12 |
| Fatigue | 74 | 4.5% | 15 | 25 |
| Pyrexia | 73 | 4.4% | 11 | 52 |
| Dehydration | 69 | 4.2% | 4 | 62 |
| Thrombocytopenia | 62 | 3.8% | 15 | 21 |
| Dyspnoea | 59 | 3.6% | 16 | 27 |
Other Indications for TEMSIROLIMUS
Metastatic renal cell carcinoma (131)
Embryonal rhabdomyosarcoma (121)
Product used for unknown indication (88)
Renal cancer (69)
Mantle cell lymphoma (65)
Neoplasm malignant (60)
Rhabdomyosarcoma (51)
Alveolar rhabdomyosarcoma (38)
Metastatic malignant melanoma (35)
Renal cancer metastatic (29)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)